Engineered Yeast Pathways for Low-Cost Thebaine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for manufacturing benzylisoquinoline alkaloids, including thebaine and other morphinan alkaloids, suffer from low yields and high costs, and lack commercially viable biosynthetic production methods.
Innovation Solution
Genetic engineering of microorganisms to produce benzylisoquinoline alkaloids by encoding heterologous enzymes for specific reactions, using enzymes such as thebaine synthesis polypeptides and purine permeases to convert sugar substrates into thebaine and derivatives, with optional in vitro and in vivo processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing manufacturing methods are used, then production can be achieved, but yields are low and costs are high
Solution Approach 1:
The patent replaces conventional chemical synthesis methods with a biological system (yeast cell) that performs the biosynthetic pathway naturally. The yeast cell contains engineered enzymes (tyrosine hydroxylase, DOPA decarboxylase, norcoclaurine synthase, etc.) that convert sugar substrates into thebaine through a series of enzymatic reactions, eliminating the need for complex chemical manufacturing processes and reducing both cost and improving yield.
Solution Approach 2:
The patent modifies the metabolic parameters of the yeast cell by introducing specific genes (TYR, DODC, NCS, 6OMT, CNMT, NMCH, 4OMT, CPR, SAS, SalR, SalAT) that encode enzymes for the biosynthetic pathway. This genetic modification changes the cell's metabolic capabilities to produce thebaine efficiently from sugar substrates, achieving high yields and low costs.
2Productivity
If conventional synthesis methods are used, then thebaine can be produced, but many undesirable morphinan alkaloid by-products are formed
Solution Approach 1:
The patent segments the biosynthetic pathway into specific enzymatic steps, each catalyzed by a dedicated enzyme (tyrosine hydroxylase for L-DOPA, DOPA decarboxylase for norcoclaurine, norcoclaurine synthase for reticuline, etc.). This segmentation allows precise control over the transformation at each stage, ensuring the formation of desired thebaine molecules while preventing unwanted by-products from forming.
Solution Approach 2:
The patent uses specific intermediate compounds (L-DOPA, norcoclaurine, reticuline, salutaridine, salutaridinol) as controlled intermediates in the biosynthetic pathway. Each intermediate is formed through a specific enzymatic reaction and serves as a controlled step toward the final thebaine product, preventing bypass reactions that would create undesirable by-products.
3Quantity of substance
If natural sources are harvested, then thebaine can be obtained, but the process is expensive and yields are limited
Solution Approach 1:
The patent employs a self-service approach by using yeast cells that can autonomously convert sugar substrates into thebaine through their engineered biosynthetic pathway. The yeast cell serves itself by utilizing readily available sugar materials (such as glucose from corn or other renewable sources) to produce thebaine, eliminating the need for expensive natural source harvesting and enabling scalable, cost-effective production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances thebaine production yields and reduces production costs by providing a biosynthetic pathway for these alkaloids, enabling their use as feedstocks for medicinal compounds.
Implementation Method 1
a cell that comprises one or more nucleic acids encoding for heterologous enzymes that can perform any one of the following reactions: i) sugar to 1-tyrosine; ii) 1-tyrosine to 1-DOPA; iii) 1-DOPA to dopamine; iv) dopamine to (S)-norcoclaurine; v) (S)-norcoclaurine to (S)/(R)-reticuline; vi) (R)-reticuline to salutardine; vii) salutardine to salutaridinol; viii) salutaridinol to salutaridinol-7-O-acetate; ix) salutaridinol-7-O-acetate to thebaine
Implementation Method 2
In some instances, a purine permease is also present within the cell
Data Source
AI summary
Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and/or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.